GlassScriptPhysician profile
Amy Jo Couch
NPI 1073297727
$7,735.47
in general payments reported to CMS, 2019-2025
22 companies · $2,966 in 2025
The $2,966 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,584 · 2024: $3,186 · 2025: $2,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,690 · Education: $45.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,690.16 |
| Education | $45.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,360.14 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $814.66 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $756.35 | 2023-2025 | Ingrezza |
| Abbvie INC. | $695.22 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $667.71 | 2023-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Axsome Therapeutics, INC. | $573.41 | 2023-2025 | Auvelity |
| Lundbeck LLC | $561.47 | 2023-2025 | Rexulti |
| Corium, LLC | $398.51 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $382.29 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $361.63 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $314.14 | 2024-2025 | Wellbutrin, Aplenzin |
| Teva Pharmaceuticals USA, INC. | $252.55 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Braeburn INC. | $132.06 | 2024-2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $123.54 | 2023-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $99.18 | 2023-2024 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $59.70 | 2024-2025 | Adzenys Xr-Odt |
| Acadia Pharmaceuticals INC | $52.24 | 2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $39.51 | 2024-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $32.74 | 2023-2024 | Jornay Pm |
| Astellas Pharma US INC | $19.74 | 2024 | Veozah |
| Almatica Pharma LLC | $19.70 | 2024 | Loreev Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.98 | 2025 | Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Couch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.